Payment overview · 2025
General Payments
$544.24
24 reported records · 10 companies
Healthcare provider profile · identity verified
Robert G Curran, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MALVERNE, NY · NPI 1700820818
Verified facts
What the public records show
CMS Open Payments records show Robert G Curran, M.D. received $544.24 in general payments during 2025 across 24 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $115.39 | 21.2% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $95.69 | 17.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $82.84 | 15.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $82.31 | 15.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.45 | 6.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $32.43 | 6.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.08 | 5.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $26.67 | 4.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.14 | 4.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.24 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $544.24 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $115.39 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $95.69 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.21 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $61.21 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.27 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.45 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $36.45 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $32.43 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $32.43 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.57 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $28.08 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
24 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 717 | 203 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 596 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 488 | 125 |
| Losartan Potassium | Losartan Potassium | 454 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 382 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 345 | 101 |
| Furosemide | Furosemide | 253 | 64 |
| Zolpidem Tartrate | Zolpidem Tartrate | 200 | 36 |
| Eliquis | Apixaban | 199 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 53 |
| Famotidine | Famotidine | 177 | 47 |
| Ezetimibe | Ezetimibe | 174 | 53 |
| Omeprazole | Omeprazole | 164 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 163 | 48 |
| Potassium Chloride | Potassium Chloride | 144 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 47 |
| Allopurinol | Allopurinol | 141 | 36 |
| Metformin Hcl | Metformin Hcl | 141 | 43 |
| Alprazolam | Alprazolam | 138 | 50 |
| Gabapentin | Gabapentin | 137 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 49 |
| Lisinopril | Lisinopril | 125 | 33 |
| Simvastatin | Simvastatin | 121 | 33 |
| Jardiance | Empagliflozin | 118 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 34 |
| Atenolol | Atenolol | 89 | 27 |
| Donepezil Hcl | Donepezil Hcl | 82 | 29 |
| Synthroid | Levothyroxine Sodium | 74 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 28 |
| Glimepiride | Glimepiride | 63 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 19 |
| Azithromycin | Azithromycin | 61 | 54 |
| Mirtazapine | Mirtazapine | 61 | 15 |
| Lorazepam | Lorazepam | 60 | 12 |
| Tramadol Hcl | Tramadol Hcl | 60 | 15 |
| Metformin Hcl Er | Metformin Hcl | 58 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 14 |
| Nifedipine Er | Nifedipine | 57 | 13 |
| Finasteride | Finasteride | 56 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 55 | 14 |
| Digoxin | Digoxin | 55 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 18 |
| Alendronate Sodium | Alendronate Sodium | 51 | 16 |
| Myrbetriq | Mirabegron | 51 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | 14 |
| Methylprednisolone | Methylprednisolone | 49 | 44 |
| Ramipril | Ramipril | 49 | 14 |
| Trazodone Hcl | Trazodone Hcl | 46 | 15 |
| Metolazone | Metolazone | 45 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 41 | 12 |
| Sertraline Hcl | Sertraline Hcl | 41 | 12 |
| Irbesartan | Irbesartan | 40 | 13 |
| Latanoprost | Latanoprost | 39 | suppressed |
| Meloxicam | Meloxicam | 39 | 15 |
| Memantine Hcl | Memantine Hcl | 39 | 12 |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 30 |
| Montelukast Sodium | Montelukast Sodium | 35 | 11 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Prednisone | Prednisone | 31 | 17 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | 11 |
| Ozempic | Semaglutide | 30 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Klor-Con M10 | Potassium Chloride | 27 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Torsemide | Torsemide | 26 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Mupirocin | Mupirocin | 24 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Prolia | Denosumab | 24 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 22 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 23 | 20 |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 11 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 16 | 13 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Cefadroxil | Cefadroxil | 13 | 12 |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $544.24 · 24 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AREXVY, CAPLYTA, CAPVAXIVE, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GARDASIL 9, KISUNLA, Leqembi, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error